Theratechnologies and TaiMed Biologics Sign Exclusive

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Theratechnologies and TaiMed Biologics Sign Exclusive Marketing and Distribution Agreement for Ibalizumab

MONTRÉAL, QUÉBEC--(Marketwired - March 18, 2016) - Theratechnologies inc. (TSX:TH) and TaiMed Biologics, Inc. today announced a 12-year collaboration agreement to market and distribute ibalizumab in the United States and in Canada. Ibalizumab is a novel CD4-directed HIV entry-inhibitor and is the first humanized monoclonal antibody in clinical trials for the treatment of HIV.

Ibalizumab is currently in a late-stage Phase III clinical trial, the last step before submitting the product for regulatory approval to the Food and Drug Administration in the United States ("FDA"). Over two-thirds of patients required for the open-label, 24-week trial have been enrolled. Patient screening for this study is anticipated to close later this month. The objective of this study is to reduce viral replication in patients with multi-drug resistant HIV infection. The primary endpoint of the Phase III trial is the proportion of patients achieving a 0.5 log 10 decrease in viral load 7 days after initiating treatment.

Once the Phase III trial is completed, ibalizumab will be evaluated under the FDA's priority review process which is expected to be completed within six months of the application or during the first half of 2017.

Ibalizumab was designated a "Breakthrough Therapy" by the FDA based on preliminary clinical evidence indicating that it may represent a substantial improvement over existing therapies on one or more clinically significant endpoints. In a Phase IIb clinical trial, conducted on 113 patients, the product significantly reduced viral load in multi-drug resistant HIV-infected patients.

The US FDA has also granted ibalizumab Orphan Drug designation. This status is given to drugs and biologics that are intended for the safe and effective treatment of rare diseases/disorders that affect fewer than 200,000 persons.

Under the Biologics Price Competition and Innovation Act of 2009, ibalizumab will be granted 12 years of marketing exclusivity.

Ibalizumab is currently administered as a bi-monthly (once every two weeks) intravenous injection. TaiMed is conducting clinical trials with the same formulation for bi-monthly intramuscular injection (IM) and monthly IM administration. Theratechnologies has also secured exclusive rights to market and distribute the drug for the IM route of administration.

"Ibalizumab represents a perfect fit for our organization. It is a niche, breakthrough treatment for multi-drug resistant HIV patients. These individuals are followed by the same physicians that treat patients suffering from HIV-associated lipodystrophy. Ibalizumab fits very well within our existing commercial infrastructure, as we can leverage our salesforce, our Medical Science Liaison team as well as our Managed Markets group and call center. This is the type of products we want to add to our portfolio as they hold the potential to generate additional revenues while keeping focused on our core business," said Luc Tanguay, President and CEO, Theratechnologies inc.

"Partnering with Theratechnologies for the commercialization of ibalizumab makes perfect sense. They bring experience and knowledge of the world's largest market for our product. On our side, we will stay focused on our R&D expertise and further develop ibalizumab. We have made a transaction which will allow us to rapidly bring our product to market and to generate revenues for our company," said James Chang, Chief Executive Officer, TaiMed Biologics, Inc.

Transaction terms

The terms of the transaction include a US$2 million payment obligation, of which US$1 million was paid in cash at the signature of the agreement and US$1million will be paid at the commercial launch through the issuance of 957,169 common shares of Theratechnologies.

A further US$8.5 million will become due at commercial launch, subject to certain conditions. This amount will be payable as follows: US$2 million in common shares of Theratechnologies at a price to be determined upon FDA approval and US$1 million in common shares of Theratechnologies at a price to be determined upon commercial launch, based on the volume-weighted average trading price of Theratechnologies' common shares on the TSX prior to each of these dates and US$5.5 million, payable in quarterly installments based on a predetermined percentage of net sales during that quarter.

Once sales have reached an aggregate amount of US$20 million over 4 consecutive quarters, Theratechnologies will make a US$7 million milestone payment (payable in two installments over one year). Theratechnologies will also pay additional sales related milestones; US$10 million once annual sales of ibalizumab reach US$200 million, US$40 million once annual sales reach US$500 million, and US$100 million once annual sales reach US$1 billion.

Theratechnologies will also pay development milestones to TaiMed. A US$3 million milestone is due upon the approval of the twice-monthly (once every two weeks) intramuscular route of administration, again payable in two installments over one year. TaiMed will also be planning a larger Phase III trial with the once-monthly (once every four weeks) intramuscular or subcutaneous route of administration, to address a much broader patient population. This development milestone will consist of an upfront milestone payment of up to US$50 million, depending on the size of the newly targeted population, which will be paid quarterly, based on a percentage of net sales generated by the product.

Pursuant to the terms of the agreement, Theratechnologies has exclusive rights to commercialize ibalizumab in the United States and in Canada. TaiMed will continue to be responsible for development of ibalizumab and seek approval from the FDA whereas Theratechnologies will be responsible to obtain the approval from Health Canada. TaiMed will manufacture and supply ibalizumab to Theratechnologies at a transfer price of 52% of net sales of the product.

Conference Call, Webcast and Slide Presentation Details

A conference call will be held today at 8:00 a.m. (ET) to discuss the transaction. The call will be hosted by Luc Tanguay, President and Chief Executive Officer. The conference call will be open to questions from financial analysts. Media and other interested individuals are invited to participate in the call on a "listen-only" basis.

The conference call can be accessed by dialing 1-877-223-4471 (North America) or 1-647-788-4922 (International). The conference call will also be accessible via webcast and will be supported by a slide presentation at http://www.gowebcasting.com/7368 .

Audio replay of the conference call will be available two hours after the call's completion until April 1, 2016, by dialing 1-800-585-8367 (North America) or 1-416-621-4642 (International) and by entering the playback code 67672037.

About Theratechnologies

Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and an improved quality of life. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com

About TaiMed Biologics

TaiMed Biologics, Inc. is a publicly held Taiwanese biotechnology company with the mission to discover, develop and deliver for the global market innovative medicines that help patients prevail over serious infectious diseases. For more information, please visit the company's website at www.taimedbiologics.com .

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, that are based on our management's belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", "would", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the approval of ibalizumab, the timelines related to the review of the application by the FDA and the revenue growth to Theratechnologies generated by the commercialization of ibalizumab.

Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies' control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include, but are not limited to, the following: ibalizumab will be approved by the FDA; the timelines disclosed in this press release to obtain the issuance of a decision from the FDA is accurate; if, and once approved, ibalizumab will be accepted by physicians and patients as a new treatment; and revenues generated from the sale of ibalizumab will grow our business and create shareholders value.

These risks and uncertainties include, but are not limited to, the risk that the Phase III trial does not generate positive data resulting in halting the development of ibalizumab or having to begin new clinical trials; the FDA does not approve ibalizumab; delays occur in completing the Phase III trial, the filing of the BLA, the issuance of the decision by the FDA and/or the commercial launch of ibalizumab; if approved, physicians and patients do not accept ibalizumab as a new treatment and, if and when approved, sales of ibalizumab do not allow us to generate enough revenues to significantly grow our business.

We refer potential investors to the "Risk Factors" section of our Annual Information Form dated February 24, 2016 available at www.sedar.com for additional risks regarding the Company and its operation. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Denis Boucher EXOCET Public Relations inc. 514-913-1957
Scroll down for more posts ▼

Top 10 Most Recent News Articles

COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 61

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 146

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Stardock Fences 7 Targets Messy Windows Desktops Everywhere

Updated Category News Views 18

A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 246

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 196

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 9

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 35

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 34

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 116

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into Abacus Global Management Inc. Stock

Updated Category News Views 231

Wolf Popper LLP Initiates Investigation for Investors In response to potential investor claims, Wolf Popper LLP has begun an investigation concerning the common stock of Abacus Global Management, Inc. (ABL). This action comes in light of significant recent developments that have raised concerns among shareholders. Background on Abacus Global Management Abacus Global...

Continue Reading
LM Funding America Inc. Reports Q3 2024 Results and Outlook

Updated Category News Views 115

Business Update and Financial Highlights LM Funding America, Inc. (NASDAQ: LMFA) has recently shared its financial results for the third quarter of 2024. This Tampa-based company focuses on cryptocurrency mining and technological finance solutions, showcasing significant strategic developments in its operations. Bitcoin Holdings and Revenue Performance As of September 30,...

Continue Reading
Siete Foods' Juntos Fund Celebrates 15 Latino-Owned Businesses

Updated Category News Views 239

Siete Foods launched its Juntos Fund back in 2024, dishing out a hefty $300,000 to uplift Latino small business owners. This initiative aimed at breaking down barriers for Latino entrepreneurs who often struggle to secure the financial backing they need. The winners? A mix of vibrant eateries and innovative food ventures that embody the rich essence of Latino culture...

Continue Reading
Discover the Fascinating Marilyn Monroe in New Documentary

Updated Category News Views 319

Big Screen Entertainment Group Unveils Marilyn Monroe Documentary Big Screen Entertainment Group (OTC: BSEG) has generated excitement with the release of its first trailer for an upcoming documentary focusing on the legendary actress Marilyn Monroe. This film, titled "Hollywood Legends: The Marilyn Monroe Story," promises to be a captivating tribute that delves into not...

Continue Reading
Transforming Dealerships: FrogData's New Marketing Solution

Updated Category News Views 120

FrogData Introduces FixedOps Velocity for Dealerships FrogData, a leader in advanced data analytics for the automotive industry, has recently launched a groundbreaking marketing solution called FixedOps Velocity. This innovative platform is aimed at helping dealership service departments enhance their marketing strategies significantly. The announcement comes just ahead...

Continue Reading